Supplementary Table 2. Comparison of Patients with Favorable Versus Unfavorable Outcomes

Variables	Total (n=195)	Outcomes		*p* value
		Favorable (n=164)	Unfavorable (n=31)	
Patient factors				
Age (yr)	56.6 (40.2–68.6)	56.0 (36.8–67.7)	62.0 (48.8–74.2)	0.073
Sex, male	113 (57.9)	91 (55.5)	22 (71.0)	0.118
Body mass index, kg/m^2	20.8 (19.2–23.1)	20.8 (19.3–23.1)	20.7 (18.6–22.8)	0.965
Underlying disease				
Hypertension	56 (28.7)	43 (26.2)	13(41.9)	0.086
Diabetes mellitus	38 (19.5)	31 (18.9)	7 (22.6)	0.626
Malignancy	35 (17.9)	24 (14.6)	11 (35.5)	0.010
Respiratory disease	31 (15.9)	29 (17.7)	2 (6.5)	0.178
Chronic kidney disease	13 (6.7)	8 (4.9)	5 (16.1)	0.037
Immunocompromised*	12 (6.2)	9 (5.5)	3 (9.7)	0.410
Smoking history	72 (36.9)	51 (31.1)	21 (67.7)	<0.001
Prior history of TB treatment	54 (27.7)	42 (25.6)	12 (38.7)	0.188
Total protein level, g/dL	7.0 (6.7–7.4)	7.1 (6.8–7.4)	6.7 (5.9–7.4)	0.018
Albumin level, g/dL	4.0 (3.6–4.3)	4.0 (3.7–4.4)	3.2 (2.7–4.0)	<0.001
Disease factors				
Disease site				0.229
Pulmonary	182 (93.3)	151 (92.1)	31 (100.0)	
Extra-pulmonary	13 (6.7)	13 (7.9)	0	
Disease severity				
Baseline positive AFB smear	61 (31.3)	49 (29.9)	12 (38.7)	0.398
Positive AFB culture at 1 months	26 (13.3)	19 (11.6)	7 (22.6)	0.144
Positive AFB culture at 2 months	9 (4.6)	4 (2.4)	5 (16.1)	0.006
Cavitary lesions in chest radiography	51 (27.0)	40 (25.2)	11 (36.7)	0.261
Phenotypic DST				0.830
High-level resistance	138 (70.8)	115 (70.1)	23 (74.2)	
Low-level resistance	57 (29.2)	49 (29.9)	8 (25.8)	
Rapid molecular DST				
Done	145 (74.4)	120 (73.2)	25 (80.6)	0.503
Mutation	122 (84.1)	104 (86.7)	18 (72.0)	0.078
Treatment factors				
Drug regimen composition				
Fluoroquinolone use	69 (35.4)	59 (36.0)	10 (32.3)	0.838
Injectable agents use	12 (6.2)	11 (6.7)	1 (3.2)	0.695
Treatment duration, days				
Hr-TB treatment duration†	211.0 (124.0–273.0)	221.0 (162.5–287.8)	38.0 (0.0–119.0)	<0.001
Fluoroquinolone treatment duration	249.0 (185.0–312.0)	255.0 (213.5–327.5)	129.0 (48.3–195.0)	0.002
PZA treatment duration	209.0 (102.0–281.0)	268.5 (180.3–288.5)	60.0 (28.0–183.0)	<0.001
Treatment duration‡	273.0 (187.0–342.0)	275.0 (210.8–362.8)	102.0 (38.0–199.0)	<0.001
Altered Hr-TB regimen after full DST	102 (52.3)	81 (49.4)	21 (67.7)	0.097
Time to regimen change for Hr-TB	60.0 (36.5–84.5)	62.0 (38.5–85.0)	50.0 (35.5–72.0)	0.927
Length of follow-up,§ days	871.0 (472.5–1782.5)	845.0 (469.0–1691.0)	1628.0 (796.5–2834.0)	0.167
Adverse events	154 (79.0)	130 (79.3)	24 (77.4)	0.812
GI trouble	89 (45.6)	75 (45.7)	14 (45.2)	1.000
Rash	85 (43.6)	75 (45.7)	10 (32.3)	0.236
Arthritis	56 (28.7)	48 (29.3)	8 (25.8)	0.830
Drug-induced hepatitis	23 (11.8)	15 (9.1)	8 (25.8)	0.015
Hematologic abnormalities	7 (3.6)	7 (4.3)	0	0.600
Peripheral neuropathy	9 (4.6)	6 (3.7)	3 (9.7)	0.156

TB, tuberculosis; AFB, acid-fast bacillus; DST, drug-susceptibility test; Hr-TB, isoniazid-resistant tuberculosis; PZA, pyrazinamide; GI, gastrointestinal.
Data are presented as numbers (%) or medians (IQR).
*Immunocompromised patients: 1) hematopoietic cell transplant recipients, 2) other solid organ transplant recipients, and (3) patients who received any immunosuppressive treatments (e.g., biologic agents targeting inflammatory mediators or corticosteroid therapy), †Hr-TB treatment duration: time from the initiation of Hr-TB treatment to its completion, ‡Treatment duration: time from the initiation to the completion of TB treatment, §Length of follow-up: time from the initiation of TB treatment to the last follow-up.